长链非编码RNA与mRNA在胰腺癌中的差异表达及其预后价值

doi:10.3969/j.issn.1004-616x.2019.02.005

摘要/Abstract

摘要： 目的：对基因芯片表达汇编（GEO）数据库和癌症基因组图谱（TCGA）数据库中的胰腺癌数据进行生物信息学分析，探讨长链非编码RNA （lncRNA）与mRNA在胰腺癌中的差异表达和预后价值。方法：首先对GEO数据库中的胰腺癌数据注释获得mRNA和lncRNA，并对芯片中的mRNA和lncRNA取交集获得差异mRNA和lncRNA。然后对差异mRNA和lncRNA进行基因分析，同时对TCGA数据库中胰腺癌的相关数据进行生存分析。结果：通过基因分析获得与胰腺癌相关可信度高的差异mRNA 1 147个，lncRNA 336个，通过基因本体（GO）和京都基因与基因组百科全书（KEGG）分析，构建lncRNA-mRNA共表达网络、lncRNA-mRNA-pathway网络、信号通路关系网络及蛋白质相互作用网络，结果证明mRNA和lncRNA对胰腺癌的发生发展有着重要影响；生存分析发现有12个lncRNA与胰腺癌的预后相关，分别是ATP1A1-AS1、CBR3-AS1、CTD-3080P12.3、FAM66D、FAM87A、FLJ38576、LINC00476、LINC00574、LINC01554、PYY2、LINC00857、OVOL1-AS1。结论：lncRNA对胰腺癌的发生发展及预后有显著影响，有望为胰腺癌的靶向治疗和预后评估提供新的治疗靶点和分子标志物。

关键词: 胰腺癌, 长链非编码RNA, mRNA, 预后评估

Abstract: OBJECTIVE:Using bioinformatics method,the data of pancreatic cancer in Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database were analyzed to evaluate the differential expression and prognostic value of lncRNA and mRNA in pancreatic cancers.METHODS:Firstly,we annotated the data of pancreatic cancers into GEO database to extract the information on mRNA and lncRNA.By intersecting the mRNA and lncRNA in the chip,we obtained the differentially expressed mRNA and lncRNA.Then,genetic analyses of the differentially expressed mRNA and lncRNA were carried out.At the same time,survival analysis was carried out with the relevant data of pancreatic cancers in the TCGA database.RESULTS:With the gene analyses,we obtained 1 147 differentially expressed mRNAs and 336 differentially expressed IncRNAs,which were reliability related to pancreatic cancer.Through gene ontology analyses and Kyoto encyclopedia of genes and genomes analyses,networks on lncRNA-mRNA co-expression,lncRNA-mRNA-pathways,signal pathways and protein interactions were constructed.The results show that mRNAs and lncRNAs had an important impact on the occurrence and development of pancreatic cancers.Survival analysis revealed that 12 lncRNAs were associated with the prognosis of pancreatic cancer,namely ATP1A1-AS1,CBR3-AS1,CTD-3080P12.3,FAM66D,FAM87A,FLJ38576,LINC00476,LINC00574,LINC01554,PY2,LINC00857,OVOL1-AS1.CONCLUSION:Several LncRNA demonstrated a significant association with the occurrence,development and prognosis of pancreatic cancers.Therefore,they are expected to provide new therapeutic targets and molecular markers for targeted therapy as well as prognosis evaluation of pancreatic cancers.

Key words: pancreatic cancer, lncRNA, mRNA, prognosis evaluation

中图分类号:

R318.04

魏超, 张晓, 高杰. 长链非编码RNA与mRNA在胰腺癌中的差异表达及其预后价值[J]. 癌变·畸变·突变, 2019, 31(2): 119-126,132.

WEI Chao, ZHANG Xiao, GAO Jie. Expression of lncRNA and its prognostic value in pancreatic cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 119-126,132.

参考文献

[1] KAMISAWA T,WOOD L D,ITOI T,et al. Pancreatic cancer[J]. Lancet,2016,388(10039):73-85.
[2] 郭飞波,韩利蓉,余卉,等. miR-143、miR-145在胰腺癌患者血清中的表达情况及与患者临床参数的相关性分析[J]. 中国免疫学杂志,2018,34(10):1547-1551.
[3] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[4] SIEGEL R,MA J,ZOU Z,et al. Cancer statistics,2014[J]. CA Cancer J Clin,2014,64(1):9-29.
[5] FATICA A,BOZZONI I. Long non-coding RNAs:new players in cell differentiation and development[J]. Nat Rev Genet,2014,15(1):7-21.
[6] EVANS J R,FENG F Y,CHINNAIYAN A M. The bright side of dark matter:lnc RNAs in cancer[J]. J Clin Invest,2016,126(8):2775-2782.
[7] SUN J,CHEN X H,WANG Z Z,et al. A potential long noncoding RNA signature to predict metastasis-free survival of breast cancer patients[J]. Sci Rep,2015,5:16553.
[8] ZHOU M,XU W Y,YUE X L,et al. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma[J]. Oncotarget,2016,7(20):29720-29738.
[9] ZHOU M,SUN Y Y,XU W Y,et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer[J]. Oncotarget,2016,7(22):32433-32448.
[10] CHEN H Y,YU C Y,WANG J L,et al. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer[J]. Oncotarget,2014,5(8):2230-2242.
[11] ZHOU M,ZHAO H,XU W,et al. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma[J]. Mal Cancer,2017,16:16.
[12] SOHN T,YEO C,LILLEMOE K,et al. Resected adenocarcinoma of the pancreas-616 patients:Results,outcome and prognostic indicators[J]. J Gastrointest Surg,2000,4(6):567-579.
[13] THE SURGERY OF CHINESE MEDICAL ASSICIATION BRANCH OF PANCREATIC SURGERY GROUP. Guide of diagnosis and treatment of pancreatic cancer (2014 edittion)[J]. Pract Surg Mag,2014,13(11):831-837.
[14] BEEGHLYFADIEL A,LUU H N,DU L,et al. Early onset pancreatic malignancies:Clinical characteristics and survival associations[J]. Int J Cancer,2016,139(10):2169-2177.
[15] CAMARA S N,YIN T,YANG M,et al. High risk factors of pancreatic carcinoma[J]. J Huazhong Univ Sci Technol (Med Sci),2016,36(3):295-304.
[16] BANWAIT J K,BASTOLA D R. Contribution of bioinfor-matics prediction in microRNA-based cancer therapeutics[J]. Adv Drug Deliv Rev,2015,81(9):94-103.
[17] XIAOMING F,USMAN A,CHRISTOPHER D,et al. Characterization of a long non-coding RNA,the antisense RNA of Na/K-ATPase α1 in human kidney cells[J]. Int J Mol Sci,2018,19(7):2123.
[18] ZHANG Y,MENG W,CUI H. LncRNA CBR3-AS1 predicts unfavorable prognosis and promotes tumorigenesis in osteosarcoma[J]. Biomed Pharma,2018,102:169-174.
[19] LI J,LI C,WANG J,et al. Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq[J]. Oncotarget,2016,8(3):4585.
[20] YIN X,BIZON C,TILSON J,et al. Genome-wide meta-analysis identifies a novel susceptibility signal at\r,CACNA2D3\r,for nicotine dependence[J]. Am J Med Genet B:Neuropsych Gene,2017,174B:557-567.
[21] HAIRRONG L,JUAN L,PRATIRODH K,et al. Long non-coding RNAs as prognostic markers in human breast cancer[J]. Oncotarget,2016,7(15):20584-20596.
[22] FAN Q,LIU B. Identification of a RNA-Seq based 8-long non-coding RNA signature predicting survival in esophageal cancer[J]. Med Sci Monit,2016,22:5163-5172.
[23] COUZENS M,LIU M,CAMILLA T,et al. Peptide YY-2(PYY2) and pancreatic polypeptide-2(PPY2):Species-specific evolution of novel members of the neuropeptide Y gene family[J]. Genomics,2000,64(3):1-323.
[24] WANG L,HE Y,LIU W,et al. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer[J]. Oncotarget,2016,7(10):11487-11499.
[25] ZHU T,GAO Y F,CHEN Y X,et al. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer[J]. Oncotarget,2017,8(13):21281-21289.
[26] LI H,WANG X,YUAN F,et al. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma[J]. Oncotarget,2017,8(32):52571-52583.
[27] HUANG F T,PENG J F,CHENG W J,et al. MiR-143 targeting TAK1 attenuates pancreatic ductal adeno-carcinoma progression via MAPK and NF-κB pathway in vitro[J]. Dig Dis Sci,2017,62(4):944-957.
[28] ZHAO L,KONG H,SUN H,et al. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448[J]. J Cell Physiol,2018,233(5):4044-4055.
[29] ZHOU Y,CHEN Y,DING W,et al. LncRNA UCA1 impacts cell proliferation,invasion,and migration of pancreatic cancer through regulating miR-96/r,FOXO3[J]. IUBMB Life,2018,70(4):276-290.
[30] ZHANG M,ZHAO Y,ZHANG Y,et al. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells,via,the Hippo pathway[J]. BBA-Mol Basis Dis,2018,1864(5 Pt A):1770-1782.
[31] LIU S,RAMKRISHNA M,ZHAO M M,et al. The potential roles of long noncoding RNAs (lncRNA) in glioblastoma development[J]. Mol Cancer Ther,2016,15(12):2977.
[32] 涂晓丽,文荃,闫军. HBV~+肝细胞癌患者lncRNA-mRNA共表达网络分析及作用[J]. 第三军医大学学报,2018,40(1):37-44.
[33] GONGJIE T,TAO Z,XINBO W,et al. Sub-pathway analysis for severe burns injury patients:Identification of potential key lncRNAs by analyzing lncRNA-mRNA profile[J]. Exp Ther Med,2018,15(6):5281-5287.